Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Case Study
  • Published:

Rituximab treatment for a patient with type I cryoglobulinemic glomerulonephritis

Nature Clinical Practice Nephrology volume 4, pages 393–397 (2008)Cite this article

Abstract

Background A 74-year-old woman with a history of type I cryoglobulinemia with glomerulonephritis that had been successfully treated with plasmapheresis and cyclophosphamide approximately 9 years earlier presented with hemoptysis and mediastinal lymphadenopathy. Evaluation revealed the reappearance of cryoglobulins and nephrotic-range proteinuria. In addition, the patient's serum creatinine level, which had been stable for approximately 9 years after her first treatment, had increased from 79.2 µmol/l (0.9 mg/dl) to 281.6 µmol/l (3.2 mg/dl) over 6 months.

Investigations Physical examination, serum and urine laboratory analyses, CT scan, mediastinoscopy with lymph node biopsy, bone marrow biopsy, flow cytometry analysis of bone marrow, peripheral blood and lymph node tissue, and percutaneous ultrasound-guided renal biopsy.

Diagnosis Type I cryoglobulinemic glomerulonephritis associated with a CD20+ lymphoid disorder.

Management One plasmapheresis treatment, one dose of cyclophosphamide, and four weekly cycles of rituximab.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Histologic examination of the patient's first renal biopsy.
Figure 2: Changes in serum creatinine and cryoglobulin levels over the patient's clinical course.
Figure 3: Histologic examination of the patient's second renal biopsy.

References

  1. Taal BG and Schalm SW (1985) Cryoglobulins in primary biliary cirrhosis: prevalence and modulation by immunosuppressive therapy [German]. Z Gastroenterol 23: 228–234

    CAS  PubMed  Google Scholar 

  2. Karras A et al. (2002) Renal involvement in monoclonal (type I) cryoglobulinemia: two cases associated with IgG3 cryoglobulin. Am J Kidney Dis 40: 1091–1096

    Article  Google Scholar 

  3. Kimby E (2005) Tolerability and safety of rituximab. Cancer Treat Rev 31: 456–473

    Article  CAS  Google Scholar 

  4. Rosenthal E et al. (2001) Polyneuropathy and vasculitis associated with IgG type I cryoglobulinemia can be treated effectively with the anti-CD20 monoclonal antibody (rituximab). Blood 98 (Suppl): S292b

    Google Scholar 

  5. Nehme-Schuster H et al. (2005) Rituximab inefficiency during type I cryoglobulinaemia. Rheumatology (Oxford) 44: 411–413

    Article  Google Scholar 

  6. Zaja F et al. (2003) Efficacy and safety of rituximab in type 2 mixed cryoglobulinemia. Blood 101: 3827–3834

    Article  CAS  Google Scholar 

  7. Roccatello D et al. (2004) Long-term effects of anti-CD20 monoclonal antibody treatment of cryoglobulinaemic glomerulonephritis. Nephrol Dial Transplant 19: 3054–3061

    Article  CAS  Google Scholar 

  8. Arzoo K et al. (2002) Treatment of refractory antibody mediated autoimmune disorders with an anti-CD20 monoclonal antibody (rituximab). Ann Rheum Dis 61: 922–924

    Article  CAS  Google Scholar 

  9. Sansonno D et al. (2003) Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon with an anti-CD20. Blood 101: 3818–3826

    Article  CAS  Google Scholar 

  10. Ghijsels E et al. (2004) Anti-CD20 monoclonal antibody (rituximab) treatment for hepatitis C-negative therapy-resistant essential mixed cryoglobulinemia with renal and cardiac failure. Am J Kidney Dis 43: e34–e38

    Article  Google Scholar 

  11. Tedeschi A et al. (2007) Cryoglobulinemia. Blood Rev 21: 183–200

    Article  CAS  Google Scholar 

  12. Visentini M et al. (2007) Efficacy of low-dose rituximab for mixed cryoglobulinemia. Clin Immunol 125: 30–33

    Article  CAS  Google Scholar 

  13. Chu D et al. (2007) Severe, refractory non-malignant type I cryoglobulinemia treated with alemtuzumab. Rheumatol Int 27: 1173–1175

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. A Singh is an Assistant Professor and NF Rossi is a Professor in the Division of Nephrology in the Department of Internal Medicine at Wayne State University School of Medicine, S Pandrangi is a Nephrology Fellow, Detroit, MI 48201, USA.,

    Sushma Pandrangi, Atul Singh & Noreen F Rossi

  2. DE Wheeler is Associate Professor of Pathology and Laboratory Medicine at the University of South Florida, Tampa, FL, USA.,

    Donald E Wheeler

Authors
  1. Sushma Pandrangi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Atul Singh
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Donald E Wheeler
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Noreen F Rossi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Noreen F Rossi.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pandrangi, S., Singh, A., Wheeler, D. et al. Rituximab treatment for a patient with type I cryoglobulinemic glomerulonephritis. Nat Rev Nephrol 4, 393–397 (2008). https://doi.org/10.1038/ncpneph0823

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpneph0823

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing